Mesoblast and oaktree capital enter into refinancing and expansion of senior debt facility

New york, nov. 21, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has successfully refinanced its existing senior debt facility with a new us$90 million five year facility provided by funds managed by oaktree capital management, l.p. (“oaktree”).
MESO Ratings Summary
MESO Quant Ranking